Edition:
United Kingdom

People: Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

0.46USD
9:00pm BST
Change (% chg)

$0.02 (+4.55%)
Prev Close
$0.44
Open
$0.44
Day's High
$0.46
Day's Low
$0.41
Volume
34,785
Avg. Vol
37,560
52-wk High
$1.84
52-wk Low
$0.26

Carter, Kenneth 

Dr. Kenneth C. Carter, Ph.D. will be appointing as a Executive Chairman of the Board of the company, Effective January 01, 2019. Dr. Carter is a dynamic industry executive and scientific leader with deep experience in development-stage biotechnology companies. Over the past decade, he has helped found and lead several companies including NexImmune, Inc., an immuno-oncology company which he helped spin out from John Hopkins University and served as CEO from inception in 2011 until June 2017. He also co-founded and is currently Chairman of the Board of Noble Life Sciences, Inc, a pre-clinical contract research organization that enables translational science and product development for biotechnology and pharmaceutical companies. Dr. Carter was also co-founder and CEO of Avalon Pharmaceuticals from inception in 1999 until the Company's merger with Clinical Data in 2009 and led Avalon's initial public offering on the NASDAQ stock exchange in 2004. Under Dr. Carter's leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and successfully secured R&D partnerships with Merck, Novartis, Sanofi-Aventis and MedImmune.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --